• C Motzkus-Feagans, A L Pakyz, S M Ratliff, J S Bajaj, and K L Lapane.
• Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA.
• Aliment. Pharmacol. Ther. 2013 Sep 1; 38 (6): 611-8.

BackgroundEvidence about the beneficial effects of statins on reducing infections is accumulating. Identifying ways to reduce infection risk in patients with cirrhosis is important because of increased mortality risk and costs associated with infections.AimTo estimate the extent to which statin use prolongs time to infection among patients with cirrhosis.MethodsWe identified Veterans with cirrhosis, but without decompensation (n = 19 379) using US Veterans Health Administration data from 2001 to 2009. New users of statins were identified and propensity matched to non-users and users of other cholesterol-lowering medications (1:1 matching). The cohort was followed up for hospitalisations with infections. Cox regression models with time-varying exposures provided estimates of adjusted hazard ratios (HR) and 95% confidence intervals (CI).ResultsNew statin use was present among 13% of VA patients with cirrhosis without decompensation. Overall, 12.4% of patients developed a serious infection, and 0.1% of patients died. In the propensity-matched sample, statin users experienced hospitalisations with infections at a rate 0.67 less than non-users (95% Confidence Interval: 0.47-0.95).ConclusionsInfections are a major concern among cirrhotic patients and have the potential to seriously impact both life expectancy and quality of life. Statin use may potentially reduce the risk of infections among patients with cirrhosis.© 2013 John Wiley & Sons Ltd.

30 keywords...

hide…